Non-small Cell Lung Carcinoma Clinical Trial
Official title:
Evaluation of Tumor and Blood Immune Biomarkers in Resected Non-small Cell Lung Cancer
The hypothesis of this study is that functional tumor infiltrating lymphocyte (TIL) isolation from resected lung cancer specimens is feasible, allowing determination of tumor antigen-specific T cell reactivities. The primary objective of this study is to investigate the feasibility of isolating functional tumor infiltrating lymphocytes s(TILs) to determine tumor antigen-specific T cell re-activities in 30 resected lung tumor specimens. Successful isolation of TILs will be defined as collecting 1x10-6 viable, CD45+ mononuclear cells or greater from tumors containing >/=1 gram of excess tissue. If successful isolation of TILs can be obtained from >/= 66% of resected tumor specimens, the protocol will be considered feasible. The primary exploratory objective is to identify immunologic signatures that predict clinical outcomes from cytotoxic chemotherapy and/or immunotherapy.
Investigating tumor infiltrating lymphocytes in Non-small Cell Lung Cancer (NSCLC) is of
clinical importance for multiple reasons. Cellular, antigen, and cytokine profiles associated
with favorable clinical outcomes after therapy are currently lacking in lung cancer, and
these results may lead to the development of clinically important prognostic and predictive
biomarkers. Additionally, by determining the specific cell types and antigen targets of
effector cells in the microenvironment, strategies can be devised to alter mechanisms
regulating tumor immune tolerance. These data may ultimately enable future, novel
combinational approaches of anti-tumor therapies through early phase clinical trials designed
to improve clinical outcomes for patients with lung cancer. Finally, by correlating
immunologic profiles with clinical outcomes (including pathologic response and progression
free survival), signatures can be derived to help predict benefit from cytotoxic chemotherapy
for patients receiving these treatments.
This study will plan to enroll a total of 30 patients. This number will consist of a
combination of early stage NSCLC patients receiving no neoadjuvant therapy, standard
neoadjuvant cytotoxic chemotherapy, or immune checkpoint therapy as well as patients with
metastatic disease undergoing tumor resection that have received prior systemic therapy of
interest, including but not limited to anti-PD1/PDL agents.
Standard diagnostic and staging work up will be performed, including pathologic/histologic
diagnosis of cancer. Patients will receive therapy as deemed appropriate by their treating
physician as per standard clinical care or as part of a clinical cancer trial. There is no
randomization nor stratification. Patients will not receive any information about the
assays/research performed as these are for research purposes only.
Data from patients will be extracted from medical records and images. Data elements that will
be extracted include the following: age, sex, tumor histology and stage, chemotherapy
regimens and immune-modulating therapy dose and schedule, disease response (outcomes).
Tumor specimen samples will be collected at the time of definitive surgical resection of
tumor. After the specimen has been processed for margin status and the frozen section
assessment of the specimen is complete, a specimen of excess tumor (at least 1gm) will be
released and acquired by the tumor immunology correlative science staff for isolation of
tumor infiltrating lymphocytes for purposes of this protocol with any remaining tissue to be
processed by the Duke Biorepository staff if the subject has consented to biobanking. For
those subjects that decline participation in this biorepository tissue will be processed as
outlined above.
Blood will be collected prior to surgery to assess activated CD8+ T cells with specificity
against tumor antigens and CD4 and CD8 functional memory.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05110196 -
Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.
|
Phase 4 | |
Completed |
NCT02795156 -
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
|
Phase 2 | |
Terminated |
NCT02556593 -
IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases
|
Phase 2 | |
Active, not recruiting |
NCT03678350 -
Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
|
Phase 1 | |
Recruiting |
NCT05358249 -
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
|
Phase 1/Phase 2 | |
Recruiting |
NCT02273271 -
Evaluation of FLT-PET and DWI-MRI in Patients With NSCLC Treated With a Platinum-based Doublet as Preoperative Chemo
|
N/A | |
Withdrawn |
NCT03408561 -
Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer
|
N/A | |
Active, not recruiting |
NCT04984811 -
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
|
Phase 2 | |
Completed |
NCT02922777 -
Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.
|
Phase 1 | |
Active, not recruiting |
NCT01279408 -
Observing Patients With Palliative Asymptomatic Centrally Located Advanced Non-small Cell Lung Carcinoma (NSCLC)
|
||
Completed |
NCT00081315 -
Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03731585 -
Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small Cell Lung Cancer Undergoing Treatment
|
N/A | |
Active, not recruiting |
NCT02009449 -
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00540514 -
Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT03849469 -
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06222489 -
Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT
|
Phase 2 | |
Active, not recruiting |
NCT03752398 -
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
|
Phase 1 | |
Terminated |
NCT01288430 -
A Study of DS-2248 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05642195 -
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT02394548 -
Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung Cancer
|
N/A |